Literature DB >> 15012644

Evidence of thymic reconstitution after highly active antiretroviral therapy in HIV-1 infection.

G Hardy1, S Worrell, P Hayes, C M Barnett, D Glass, J Pido-Lopez, N Imami, R Aspinall, J Dutton, B Gazzard, A M Peters, F M Gotch.   

Abstract

OBJECTIVES: We aimed to provide evidence of thymic reconstitution after highly active antiretroviral therapy (HAART) in HIV-1 infected patients and to correlate this with the restoration of peripheral naïve T cells.
METHODS: Positron emission tomography (PET) enables definitive evidence of thymic activity, indicating functional potential. In this case study, a single patient who initiated HAART demonstrated reconstitution of the naïve T-cell pool and underwent thymic PET scans at baseline and 2 and 6 months following initiation of therapy. Two patients who failed to demonstrate such reconstitution acted as controls. These patients (mean age 27 years) had chronic HIV infection with low CD4 T-cell counts (mean 82, range 9-160 cells/microL blood). Increased function of the thymus visualized by PET was correlated with phenotypic changes in CD4 and CD8 T cells in the periphery measured by flow cytometry, and with numbers of recent thymic emigrants measured by quantification of the numbers of T-cell receptor excision circles (TRECs) in peripheral cells.
RESULTS: In one patient, clear correlations could be drawn between visible activity within the thymus, as measured by increased [F18]fluorodeoxyglucose (FDG) uptake, and regeneration of naïve CD4 (CD45RA/CD62L) T cells, increased numbers of CD4 T cells, controlled viraemia and increased numbers of recent thymic emigrants. A second patient displayed no increase in peripheral CD4 count and no increase in thymic activity. The third patient elected to stop therapy following the 2-month time point.
CONCLUSIONS: The use of PET suggests that thymic activity may increase after HAART, indicating that the thymus has the potential to be functional even in HIV-1 infected persons with low CD4 T-cell counts.

Entities:  

Mesh:

Year:  2004        PMID: 15012644     DOI: 10.1111/j.1468-1293.2004.00187.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  7 in total

Review 1.  Thymic function in HIV infection.

Authors:  Rohan Hazra; Crystal Mackall
Journal:  Curr HIV/AIDS Rep       Date:  2005-02       Impact factor: 5.071

2.  Thymopoietic and bone marrow response to murine Pneumocystis pneumonia.

Authors:  Xin Shi; Ping Zhang; Gregory D Sempowski; Judd E Shellito
Journal:  Infect Immun       Date:  2011-02-22       Impact factor: 3.441

Review 3.  The Role of Nuclear Medicine in the Staging and Management of Human Immune Deficiency Virus Infection and Associated Diseases.

Authors:  Alfred O Ankrah; Andor W J M Glaudemans; Hans C Klein; Rudi A J O Dierckx; Mike Sathekge
Journal:  Nucl Med Mol Imaging       Date:  2016-05-25

4.  CD4+ T cell depletion, immune activation and increased production of regulatory T cells in the thymus of HIV-infected individuals.

Authors:  Alessandra Bandera; Giulio Ferrario; Marina Saresella; Ivana Marventano; Alessandro Soria; Fabio Zanini; Francesca Sabbatini; Monica Airoldi; Giulia Marchetti; Fabio Franzetti; Daria Trabattoni; Mario Clerici; Andrea Gori
Journal:  PLoS One       Date:  2010-05-24       Impact factor: 3.240

Review 5.  Positron emission tomography in patients suffering from HIV-1 infection.

Authors:  Mike Sathekge; Ingeborg Goethals; Alex Maes; Christophe van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-04-07       Impact factor: 9.236

Review 6.  Human T cell reconstitution in DiGeorge syndrome and HIV-1 infection.

Authors:  Lori L Hudson; M Louise Markert; Blythe H Devlin; Barton F Haynes; Gregory D Sempowski
Journal:  Semin Immunol       Date:  2007-11-26       Impact factor: 11.130

7.  Levels of CD56+TIM-3- effector CD8 T cells distinguish HIV natural virus suppressors from patients receiving antiretroviral therapy.

Authors:  Bhawna Poonia; C David Pauza
Journal:  PLoS One       Date:  2014-02-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.